ICP-723 not checked
Beijing InnoCare Pharma Tech Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ICP-723 tablet administered orally,once a day,for every 28 days as one cycle”In the company’s words, NCT05745623 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion, Solid Tumors
- Main trialPhase 1/2
- “A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients with Advanced Solid Tumors or Primary Central Nervous System Tumors”In the company’s words, NCT05745623 on ClinicalTrials.gov
Other drugs for Solid Tumors
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 25 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 25 Jan 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 25 Dec 2027 | Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors | |
| Phase 1/2Recruiting | 25 Jan 2028 | A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors | |
| Phase 1Unknown | Nov 2023 | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026